Literature DB >> 6993212

Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma.

F Cavalli, A Goldhirsch, P Siegenthaler, S Kaplan, M Beer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6993212     DOI： 10.1016/0014-2964(80)90201-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.

Authors:  J F Bishop; R Kefford; D Raghavan; J Zalcberg; R Stuart-Harris; D Ball; I N Olver; M Friedlander; C Bull; K Yuen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Authors:  Y Sasaki; T Shinkai; K Eguchi; T Tamura; Y Ohe; T Ohmori; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

4.  Vindesine/cisplatin chemotherapy in relapsed or primarily resistant small-cell carcinoma of the lung.

Authors:  N Niederle; J Schütte; W Krischke; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.